Today: 9 June 2026
Lithium price rises in China, but Albemarle stock sinks after Kemerton plant goes idle
12 February 2026
2 mins read

Lithium price rises in China, but Albemarle stock sinks after Kemerton plant goes idle

New York, February 12, 2026, 12:57 (ET) — Regular session

  • Albemarle slid after it moved to idle Kemerton’s remaining processing train in Western Australia.
  • China’s battery-grade lithium carbonate prices edged up again, but spot trading stayed thin, SMM reported.
  • Traders are weighing supply curbs against fresh projects, including Congo’s Manono output targeted for June.

Albemarle shares fell 6.8% to $163.50 on Thursday after the company said it would idle the remaining operating “train,” or processing unit, at its Kemerton lithium hydroxide plant in Western Australia, effective immediately. Chief executive Kent Masters said “recent lithium price improvements” were “not enough” to offset the strain on “Western hard-rock lithium conversion operations.” Albemarle

The move matters because investors have been watching for signs that high-cost capacity is finally coming out of the system after a long price slide hammered margins across the battery-materials chain. Kemerton was built to support a Western supply chain, but the economics have been hard to make work outside China’s dominant refining base.

It also lands as traders try to pin down whether the latest uptick in lithium prices is a bounce or the start of something steadier. Spot pricing in China is still the reference point for much of the market, and any slowdown there tends to show up quickly in producer cash flow.

Shanghai Metals Market put its battery-grade lithium carbonate index at 142,168 yuan per metric ton on Thursday, with battery-grade prices at 138,000–147,000 yuan/mt. SMM said transactions were sluggish as logistics slowed and downstream buyers largely finished stockpiling for February.

The plant decision followed Albemarle’s quarterly results, where the company swung deeper into the red. Albemarle posted a fourth-quarter net loss attributable to shareholders of $455.9 million, or $3.87 per share, and an adjusted loss of 53 cents per share, Reuters reported, citing LSEG consensus that had pointed to a 41-cent loss.

In its earnings release, Albemarle laid out price-linked scenarios that underline how exposed the business remains to the lithium tape. Using an “observed market price” case tied to roughly $20/kg lithium market prices (lithium carbonate equivalent, a standard way to compare lithium chemicals), Albemarle projected 2026 net sales of $5.7–$6.0 billion and adjusted EBITDA of $2.4–$2.6 billion; at about $10/kg, the ranges fall to $4.1–$4.3 billion and $0.9–$1.0 billion. The company also pegged 2026 capex at $550–$600 million and said about 40% of its salts volume sits on long-term agreements. Albemarle

Weakness spilled across the space. Chilean miner SQM fell 5.3% to $71.28, Lithium Americas dropped 4.8% to $4.53, Sigma Lithium slid 3.7% to $13.12, and the Global X Lithium & Battery Tech ETF was down 2.2% at $72.16.

Still, shutdown headlines do not guarantee a clean rebound in the lithium price. Demand can wobble quickly with EV sales and battery inventories, and producers have been cautious about calling the bottom after repeated false starts.

Supply is the other problem. China’s Zijin will start Congo’s first lithium output in June from the disputed Manono deposit and move straight to exports, Reuters reported, quoting Cominiere managing director Alpha Monga Mwidia: “Manono Lithium will produce its first tons in June, and exports will begin immediately after.” Traders are watching whether Manono hits that June start — and whether more conversion capacity follows Kemerton into care and maintenance — as the next test of how tight the lithium market can get in 2026. Reuters

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Previous Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Anglo American share price in focus before London open as De Beers sale, results loom
Next Story

Anglo American share price in focus before London open as De Beers sale, results loom

Go toTop